| 1 |
Guideline KDIGO clinical practice guidelines on hepatitis C in chronic kidney disease acknowledged by ISN. 2008
Abboud O, Becker G, Bellorin-Font E, Field M, Johnson R, Li PK, Wanner C, Anonymous00051. · Clinical Practice Guidelines Committee of the International Society of Nephrology. · Nat Clin Pract Nephrol. · Pubmed #18813232 No free full text.
This publication has no abstract.
|
| 2 |
Article P4 and P1' optimization of bicycloproline P2 bearing tetrapeptidyl alpha-ketoamides as HCV protease inhibitors. 2004
Yip Y, Victor F, Lamar J, Johnson R, Wang QM, Glass JI, Yumibe N, Wakulchik M, Munroe J, Chen SH. · Lilly Research Laboratory, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. · Bioorg Med Chem Lett. · Pubmed #15341970 No free full text.
Abstract: With the aim of improving HCV protease inhibitors reported in our previous manuscripts, we synthesized and evaluated a series of 1a-based tetrapeptidyl alpha-ketoamides with additional P4 modification. The promising analog discovered through this SAR, 5a, was further derivatized at P1' or P1 position. As a result of these efforts, we found that replacement of the P4 valine as seen in 1a with cyclohexylglycine (Chg) resulted in the discovery of 5a, 5c, and 5e endowed with improved cellular activity in comparison to 1a.
|
| 3 |
Article Discovery of a novel bicycloproline P2 bearing peptidyl alpha-ketoamide LY514962 as HCV protease inhibitor. 2004
Yip Y, Victor F, Lamar J, Johnson R, Wang QM, Barket D, Glass J, Jin L, Liu L, Venable D, Wakulchik M, Xie C, Heinz B, Villarreal E, Colacino J, Yumibe N, Tebbe M, Munroe J, Chen SH. · Lilly Research Laboratory, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. · Bioorg Med Chem Lett. · Pubmed #14684337 No free full text.
Abstract: We describe herein the design, syntheses and evaluation of a number of bicycloproline P2 bearing HCV protease inhibitors endowed with impressive enzyme potency, enzyme selectivity, cellular activity and favorable ADME profiles.
|
| 4 |
Article Hepatic hydropericardium. 2004
Cheung TK, Tam W, Bartholomeusz D, Harley H, Johnson R. · Department of Gastroenterology, Hepatology and General Medicine, Royal Adelaide Hospital, Adelaide, South Australia, Australia. · J Gastroenterol Hepatol. · Pubmed #14675253 No free full text.
Abstract: A 41-year-old man with chronic hepatitis C and cirrhosis presented with pericardial effusion and tamponade requiring pericardiocentesis. Nine liters of pericardial fluid was drained with complete resolution of his ascites. He represented with recurrent pericardial effusions despite salt restriction and diuretic therapy. Subsequent radionuclide scans demonstrated a direct connection between the peritoneal and pericardial spaces. A pericardial window was formed but despite this there was recurrence of pericardial effusion and pleural effusion. The patient underwent orthotopic liver transplantation 7 months later and no recurrence of pleural or pericardial effusion was observed following transplantation. We believe this is the first case report of pericardial effusion secondary to cirrhotic ascites and a communication between the peritoneal and pericardial cavities.
|
|
|